about
A proposal to prevent omissions and delays of antiparkinsonian drug administration in hospitalsAcute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department.Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease.Anticholinergic burden in Parkinson's disease inpatients.Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database.Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature.Levofloxacin-induced delirium in a patient suffering from schizoaffective disorder and multiple sclerosis.Medication errors in Parkinson's disease inpatients in the Basque Country.Antipsychotics and seizures: higher risk with atypicals?Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database.The burden of constipation in psychiatric hospitals.Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.Eosinophilia associated with bupropion.[Comments on the second Spanish version of the STOPP-START criteria].Possible interaction between letrozole and long-acting injectable zuclopenthixol.A false positive for clozapine using high-pressure liquid chromatography with ultraviolet detection.Beers 2015 Criteria: Aripiprazole in Parkinson's Disease.Confusion regarding anticholinergic burden measurement.Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia[Miliary tuberculosis following treatment with adalimumab][Comments on the Spanish version of the STOPP/START criteria]Comments on Duran et al.'s systematic review of anticholinergic risk scales (EJCP 2DOI 10.1007/s00228-013-1499-3)Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance)Drug pollution and pharmacotherapy in psychiatry: A "platypus" in the roomClozapine-Induced Cardiomyopathy in Parkinson's DiseaseThe impact of the ambiguous definition of "month" on pharmacotherapy
P50
Q35171334-6BF8CFFF-A143-4C1C-9A8B-2044E3172AF6Q36181072-AAF612D0-20C2-40DA-A19E-B14654931EE1Q37087146-AD148EF5-23E8-4643-B60C-357F70EBA891Q38406475-5900C694-4607-4760-8F28-2C87C6A5E8BFQ38477365-D3E66B9F-9207-44BF-894D-EE2B27EE5C00Q38641172-FB1F056C-F771-4ABC-91EF-EAFFC9A3D3E1Q39363591-5C82EF7C-C388-4C93-9A2E-98CB72CE0A24Q43535579-81AFFAAB-26A3-4EAF-81A7-69D599050F4FQ45863421-B0879E23-1A74-488D-9818-A21F6B36CD04Q46062164-4DEC00B8-7392-4060-87EA-BD6C4077CAF2Q47556896-9456B42F-0C01-4E2A-A0DC-45EB76C86E9EQ47605404-A8A11CDE-AE64-4C48-89FF-0B03D57CD6F6Q48021666-1BEBECA6-6AEC-498B-B360-1F45D63BE7AAQ48463393-6E720112-4B6B-4ABF-942F-224D6ABAF74FQ50440050-846C6C75-44AB-4C9F-BC0C-7083FE3BAD0BQ50471307-37A849B9-7D7A-4D77-A893-2BA5C6A91028Q50506099-C363B341-DEB4-4E35-82FC-0DEB20DBDC5DQ50531298-FBDE28BA-6CB1-4BC5-A250-2254FA039F02Q50585434-961C4341-DB2F-4605-B5F8-988F88A2E73DQ58083410-2A931081-961F-439C-961F-9462639F4713Q81621420-D68164D8-4A97-4DEA-B9CD-04B776D981ADQ83881193-A569A764-08D8-49C3-A1BA-3C0B7DE868A7Q86903953-C7F70D19-6D1D-4529-9ABC-69784C4A2020Q90369445-6FE6761E-FCFB-4309-9F99-37D7FAF4B933Q90572206-3A0BD3C9-A637-4802-8616-DBE9C948F3EAQ91324660-00529FE4-3ED0-405C-AFDB-9BEBEE1D7A85Q92349594-F6E1F1DD-068E-46B0-863B-F796BB6FE973
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Unax Lertxundi
@en
Unax Lertxundi
@nl
type
label
Unax Lertxundi
@en
Unax Lertxundi
@nl
prefLabel
Unax Lertxundi
@en
Unax Lertxundi
@nl
P31
P496
0000-0002-9575-1602